Review



crabp ii rabbit polyclonal antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Proteintech crabp ii rabbit polyclonal antibody
    CRABP-II regulates cholesterol metabolic genes expression through cooperation with HuR. ( A ) Molecular and cellular function analysis by IPA software (Qiagen) based on gene expression microarray profiling. The altered lipid synthesis and accumulation functions upon CRABP-II knockout were listed. ( B ) Heat map of altered cholesterol metabolic genes. ( C, D, E ) Cholesterol metabolic genes expression assessed by Q-PCR. ( F ) Correlation between cholesterol metabolic genes and CRABP-II expression in human pancreatic cancer specimens by Pearson’s product-moment correlation coefficient analysis (PPMCC). Data shown here are combination of Pei Pancreas and Badea Pancrease datasets ( n = 75) from Oncomine. ( G ) Interaction between CRABP-II and HuR identified by co-immuprecipitation (co-IP). GR4000 cell lysis was incubated with anti-CRABP-II rabbit <t>polyclonal</t> antibody and the pull down proteins were separated and blotted with anti-HuR mouse monoclonal antibody. ( H ) Half-life of SREBP-1c mRNA assessed by actinomycin D treatment following with Q-PCR. ( I ) RNA-immunoprecipitation (RIP). The down pulled SREBP-1c mRNA from flagged-CRABP-II transfected CIIKO cells and empty vector transfected cells were assessed by Q-PCR. The actin mRNA was used as control. The experiment was repeated three times and the error bars present standard deviation (SD). **, p < 0.01
    Crabp Ii Rabbit Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 56 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/crabp+ii+rabbit+polyclonal+antibody/CRABP2+Antibody/pmc08903155-44-11-15
    Average 94 stars, based on 56 article reviews
    crabp ii rabbit polyclonal antibody - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling"

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    doi: 10.1186/s13046-022-02261-0

    CRABP-II regulates cholesterol metabolic genes expression through cooperation with HuR. ( A ) Molecular and cellular function analysis by IPA software (Qiagen) based on gene expression microarray profiling. The altered lipid synthesis and accumulation functions upon CRABP-II knockout were listed. ( B ) Heat map of altered cholesterol metabolic genes. ( C, D, E ) Cholesterol metabolic genes expression assessed by Q-PCR. ( F ) Correlation between cholesterol metabolic genes and CRABP-II expression in human pancreatic cancer specimens by Pearson’s product-moment correlation coefficient analysis (PPMCC). Data shown here are combination of Pei Pancreas and Badea Pancrease datasets ( n = 75) from Oncomine. ( G ) Interaction between CRABP-II and HuR identified by co-immuprecipitation (co-IP). GR4000 cell lysis was incubated with anti-CRABP-II rabbit polyclonal antibody and the pull down proteins were separated and blotted with anti-HuR mouse monoclonal antibody. ( H ) Half-life of SREBP-1c mRNA assessed by actinomycin D treatment following with Q-PCR. ( I ) RNA-immunoprecipitation (RIP). The down pulled SREBP-1c mRNA from flagged-CRABP-II transfected CIIKO cells and empty vector transfected cells were assessed by Q-PCR. The actin mRNA was used as control. The experiment was repeated three times and the error bars present standard deviation (SD). **, p < 0.01
    Figure Legend Snippet: CRABP-II regulates cholesterol metabolic genes expression through cooperation with HuR. ( A ) Molecular and cellular function analysis by IPA software (Qiagen) based on gene expression microarray profiling. The altered lipid synthesis and accumulation functions upon CRABP-II knockout were listed. ( B ) Heat map of altered cholesterol metabolic genes. ( C, D, E ) Cholesterol metabolic genes expression assessed by Q-PCR. ( F ) Correlation between cholesterol metabolic genes and CRABP-II expression in human pancreatic cancer specimens by Pearson’s product-moment correlation coefficient analysis (PPMCC). Data shown here are combination of Pei Pancreas and Badea Pancrease datasets ( n = 75) from Oncomine. ( G ) Interaction between CRABP-II and HuR identified by co-immuprecipitation (co-IP). GR4000 cell lysis was incubated with anti-CRABP-II rabbit polyclonal antibody and the pull down proteins were separated and blotted with anti-HuR mouse monoclonal antibody. ( H ) Half-life of SREBP-1c mRNA assessed by actinomycin D treatment following with Q-PCR. ( I ) RNA-immunoprecipitation (RIP). The down pulled SREBP-1c mRNA from flagged-CRABP-II transfected CIIKO cells and empty vector transfected cells were assessed by Q-PCR. The actin mRNA was used as control. The experiment was repeated three times and the error bars present standard deviation (SD). **, p < 0.01

    Techniques Used: Expressing, Cell Function Assay, Software, Gene Expression, Microarray, Knock-Out, Co-Immunoprecipitation Assay, Lysis, Incubation, RNA Immunoprecipitation, Transfection, Plasmid Preparation, Control, Standard Deviation

    Related Articles

    Expressing:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Cell Function Assay:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Software:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Gene Expression:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Microarray:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Knock-Out:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Co-Immunoprecipitation Assay:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Lysis:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Incubation:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    RNA Immunoprecipitation:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Transfection:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Plasmid Preparation:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Control:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Standard Deviation:

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).

    Article Title: Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival Signaling
    Article Snippet: All transfections were performed by using lipofectamine 3000 (Invitrogen).All transfections were performed by using lipofectamine 3000 (Invitrogen).. Page 4/26 Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10225-1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).. SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).SNIPER-11 and MV1 were synthesized by Mekoo Biosciences (Morrisville, NC).



    Similar Products

    crabp ii rabbit polyclonal antibody  (Proteintech)
    94
    Proteintech crabp ii rabbit polyclonal antibody
    CRABP-II regulates cholesterol metabolic genes expression through cooperation with HuR. ( A ) Molecular and cellular function analysis by IPA software (Qiagen) based on gene expression microarray profiling. The altered lipid synthesis and accumulation functions upon CRABP-II knockout were listed. ( B ) Heat map of altered cholesterol metabolic genes. ( C, D, E ) Cholesterol metabolic genes expression assessed by Q-PCR. ( F ) Correlation between cholesterol metabolic genes and CRABP-II expression in human pancreatic cancer specimens by Pearson’s product-moment correlation coefficient analysis (PPMCC). Data shown here are combination of Pei Pancreas and Badea Pancrease datasets ( n = 75) from Oncomine. ( G ) Interaction between CRABP-II and HuR identified by co-immuprecipitation (co-IP). GR4000 cell lysis was incubated with anti-CRABP-II rabbit <t>polyclonal</t> antibody and the pull down proteins were separated and blotted with anti-HuR mouse monoclonal antibody. ( H ) Half-life of SREBP-1c mRNA assessed by actinomycin D treatment following with Q-PCR. ( I ) RNA-immunoprecipitation (RIP). The down pulled SREBP-1c mRNA from flagged-CRABP-II transfected CIIKO cells and empty vector transfected cells were assessed by Q-PCR. The actin mRNA was used as control. The experiment was repeated three times and the error bars present standard deviation (SD). **, p < 0.01
    Crabp Ii Rabbit Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/crabp+ii+rabbit+polyclonal+antibody/CRABP2+Antibody/pmc08903155-44-11-15
    Average 94 stars, based on 1 article reviews
    crabp ii rabbit polyclonal antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti crabp ii  (Bethyl)
    91
    Bethyl rabbit polyclonal anti crabp ii
    CRABP-II regulates cholesterol metabolic genes expression through cooperation with HuR. ( A ) Molecular and cellular function analysis by IPA software (Qiagen) based on gene expression microarray profiling. The altered lipid synthesis and accumulation functions upon CRABP-II knockout were listed. ( B ) Heat map of altered cholesterol metabolic genes. ( C, D, E ) Cholesterol metabolic genes expression assessed by Q-PCR. ( F ) Correlation between cholesterol metabolic genes and CRABP-II expression in human pancreatic cancer specimens by Pearson’s product-moment correlation coefficient analysis (PPMCC). Data shown here are combination of Pei Pancreas and Badea Pancrease datasets ( n = 75) from Oncomine. ( G ) Interaction between CRABP-II and HuR identified by co-immuprecipitation (co-IP). GR4000 cell lysis was incubated with anti-CRABP-II rabbit <t>polyclonal</t> antibody and the pull down proteins were separated and blotted with anti-HuR mouse monoclonal antibody. ( H ) Half-life of SREBP-1c mRNA assessed by actinomycin D treatment following with Q-PCR. ( I ) RNA-immunoprecipitation (RIP). The down pulled SREBP-1c mRNA from flagged-CRABP-II transfected CIIKO cells and empty vector transfected cells were assessed by Q-PCR. The actin mRNA was used as control. The experiment was repeated three times and the error bars present standard deviation (SD). **, p < 0.01
    Rabbit Polyclonal Anti Crabp Ii, supplied by Bethyl, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/crabp+ii+rabbit+polyclonal+antibody/CRABP2+Antibody/pmc06461173-111-17-22
    Average 91 stars, based on 1 article reviews
    rabbit polyclonal anti crabp ii - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    rabbit polyclonal antibodies against crabp ii  (Proteintech)
    94
    Proteintech rabbit polyclonal antibodies against crabp ii
    <t>CRABP-II</t> and FABP5 expression patterns in MB cells with and without RA treatment. (A) CRABP-II and FABP5 mRNA expressions were measured using real-time RT-PCR. ** p < 0.01. (B) Immunofluorescence staining for CRABP-II and FABP5 in RA-treated MB cells. Magnified regions of each image are shown in the insets. (C) Western blot analysis of UW228-2 and Med-3 cells treated with and without RA. Grayscale quantitative analysis was performed on the Western blot results. * p < 0.05. Scale bar = 100 μm.
    Rabbit Polyclonal Antibodies Against Crabp Ii, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/crabp+ii+rabbit+polyclonal+antibody/CRABP2+Antibody/pmc09079906-67-0-5
    Average 94 stars, based on 1 article reviews
    rabbit polyclonal antibodies against crabp ii - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    rabbit polyclonal crabp ii antibody  (Novus Biologicals)
    86
    Novus Biologicals rabbit polyclonal crabp ii antibody
    <t>CRABP-II</t> and FABP5 expression patterns in MB cells with and without RA treatment. (A) CRABP-II and FABP5 mRNA expressions were measured using real-time RT-PCR. ** p < 0.01. (B) Immunofluorescence staining for CRABP-II and FABP5 in RA-treated MB cells. Magnified regions of each image are shown in the insets. (C) Western blot analysis of UW228-2 and Med-3 cells treated with and without RA. Grayscale quantitative analysis was performed on the Western blot results. * p < 0.05. Scale bar = 100 μm.
    Rabbit Polyclonal Crabp Ii Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/crabp+ii+rabbit+polyclonal+antibody/RBP2+Antibody/pm22014751-201-14-18
    Average 86 stars, based on 1 article reviews
    rabbit polyclonal crabp ii antibody - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    CRABP-II regulates cholesterol metabolic genes expression through cooperation with HuR. ( A ) Molecular and cellular function analysis by IPA software (Qiagen) based on gene expression microarray profiling. The altered lipid synthesis and accumulation functions upon CRABP-II knockout were listed. ( B ) Heat map of altered cholesterol metabolic genes. ( C, D, E ) Cholesterol metabolic genes expression assessed by Q-PCR. ( F ) Correlation between cholesterol metabolic genes and CRABP-II expression in human pancreatic cancer specimens by Pearson’s product-moment correlation coefficient analysis (PPMCC). Data shown here are combination of Pei Pancreas and Badea Pancrease datasets ( n = 75) from Oncomine. ( G ) Interaction between CRABP-II and HuR identified by co-immuprecipitation (co-IP). GR4000 cell lysis was incubated with anti-CRABP-II rabbit polyclonal antibody and the pull down proteins were separated and blotted with anti-HuR mouse monoclonal antibody. ( H ) Half-life of SREBP-1c mRNA assessed by actinomycin D treatment following with Q-PCR. ( I ) RNA-immunoprecipitation (RIP). The down pulled SREBP-1c mRNA from flagged-CRABP-II transfected CIIKO cells and empty vector transfected cells were assessed by Q-PCR. The actin mRNA was used as control. The experiment was repeated three times and the error bars present standard deviation (SD). **, p < 0.01

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling

    doi: 10.1186/s13046-022-02261-0

    Figure Lengend Snippet: CRABP-II regulates cholesterol metabolic genes expression through cooperation with HuR. ( A ) Molecular and cellular function analysis by IPA software (Qiagen) based on gene expression microarray profiling. The altered lipid synthesis and accumulation functions upon CRABP-II knockout were listed. ( B ) Heat map of altered cholesterol metabolic genes. ( C, D, E ) Cholesterol metabolic genes expression assessed by Q-PCR. ( F ) Correlation between cholesterol metabolic genes and CRABP-II expression in human pancreatic cancer specimens by Pearson’s product-moment correlation coefficient analysis (PPMCC). Data shown here are combination of Pei Pancreas and Badea Pancrease datasets ( n = 75) from Oncomine. ( G ) Interaction between CRABP-II and HuR identified by co-immuprecipitation (co-IP). GR4000 cell lysis was incubated with anti-CRABP-II rabbit polyclonal antibody and the pull down proteins were separated and blotted with anti-HuR mouse monoclonal antibody. ( H ) Half-life of SREBP-1c mRNA assessed by actinomycin D treatment following with Q-PCR. ( I ) RNA-immunoprecipitation (RIP). The down pulled SREBP-1c mRNA from flagged-CRABP-II transfected CIIKO cells and empty vector transfected cells were assessed by Q-PCR. The actin mRNA was used as control. The experiment was repeated three times and the error bars present standard deviation (SD). **, p < 0.01

    Article Snippet: Antibodies used in this study include: CRABP-II mouse mAbs (Millipore, MAB5488), CRABP-II rabbit polyclonal antibody (Proteintech, 10,225–1-AP), HuR (3A2, Santa Cruz, sc-5261), Flotilin-2 (Santa Cruz, sc-28320), GAPDH (Santa Cruz, sc-365062), and Actin (Santa Cruz, sc-1615), anti-Flag M2 mAb (Sigma, F9291), anti-Flag agarose beads (Clontech, #635,686), Ki67 (SP6, ThermoFisher, RM-9106-S0), ADRP (Novus, NB110-40,877), Caspas3 (Cell Signaling, #9662), PARP (Cell Signaling, #9542), AKT (Cell Signaling, #4691), mTOR (Cell Signaling, #2983), S6 (Cell Signaling, #2217), pAKT (S473, Cell Signaling, #9018), pmTOR (Cell Signaling, #5536), pS6 (Cell Signaling, #4858), and pGSK3β (Cell Signaling, #5558).

    Techniques: Expressing, Cell Function Assay, Software, Gene Expression, Microarray, Knock-Out, Co-Immunoprecipitation Assay, Lysis, Incubation, RNA Immunoprecipitation, Transfection, Plasmid Preparation, Control, Standard Deviation

    CRABP-II and FABP5 expression patterns in MB cells with and without RA treatment. (A) CRABP-II and FABP5 mRNA expressions were measured using real-time RT-PCR. ** p < 0.01. (B) Immunofluorescence staining for CRABP-II and FABP5 in RA-treated MB cells. Magnified regions of each image are shown in the insets. (C) Western blot analysis of UW228-2 and Med-3 cells treated with and without RA. Grayscale quantitative analysis was performed on the Western blot results. * p < 0.05. Scale bar = 100 μm.

    Journal: RSC Advances

    Article Title: Differential CRABP-II and FABP5 expression patterns and implications for medulloblastoma retinoic acid sensitivity

    doi: 10.1039/c8ra00744f

    Figure Lengend Snippet: CRABP-II and FABP5 expression patterns in MB cells with and without RA treatment. (A) CRABP-II and FABP5 mRNA expressions were measured using real-time RT-PCR. ** p < 0.01. (B) Immunofluorescence staining for CRABP-II and FABP5 in RA-treated MB cells. Magnified regions of each image are shown in the insets. (C) Western blot analysis of UW228-2 and Med-3 cells treated with and without RA. Grayscale quantitative analysis was performed on the Western blot results. * p < 0.05. Scale bar = 100 μm.

    Article Snippet: Rabbit polyclonal antibodies against CRABP-II (ProteinTech 10225-1-AP) or FABP5 (ProteinTech 12348-1-AP), were applied overnight at 4 °C.

    Techniques: Expressing, Quantitative RT-PCR, Immunofluorescence, Staining, Western Blot

    Expression patterns of CRABP-II and FABP5 in MB tissues. Immunohistochemical profiling of CRABP-II and FABP5 expression patterns in classic and large-cell MBs. The staining patterns were scored as CRABP-II↑/FABP5↓ (FABP5 down-regulated) and CRABP-II↓/FABP5↑ (FABP5 up-regulated) based on the labeling intensity of these two proteins in individual cases. The insets illustrate regions at higher magnification. Scale bar = 50 μm.

    Journal: RSC Advances

    Article Title: Differential CRABP-II and FABP5 expression patterns and implications for medulloblastoma retinoic acid sensitivity

    doi: 10.1039/c8ra00744f

    Figure Lengend Snippet: Expression patterns of CRABP-II and FABP5 in MB tissues. Immunohistochemical profiling of CRABP-II and FABP5 expression patterns in classic and large-cell MBs. The staining patterns were scored as CRABP-II↑/FABP5↓ (FABP5 down-regulated) and CRABP-II↓/FABP5↑ (FABP5 up-regulated) based on the labeling intensity of these two proteins in individual cases. The insets illustrate regions at higher magnification. Scale bar = 50 μm.

    Article Snippet: Rabbit polyclonal antibodies against CRABP-II (ProteinTech 10225-1-AP) or FABP5 (ProteinTech 12348-1-AP), were applied overnight at 4 °C.

    Techniques: Expressing, Immunohistochemical staining, Staining, Labeling

    Tissue microarray-based immunohistochemical staining of CRABP-II and FABP5 in human medulloblastomas

    Journal: RSC Advances

    Article Title: Differential CRABP-II and FABP5 expression patterns and implications for medulloblastoma retinoic acid sensitivity

    doi: 10.1039/c8ra00744f

    Figure Lengend Snippet: Tissue microarray-based immunohistochemical staining of CRABP-II and FABP5 in human medulloblastomas

    Article Snippet: Rabbit polyclonal antibodies against CRABP-II (ProteinTech 10225-1-AP) or FABP5 (ProteinTech 12348-1-AP), were applied overnight at 4 °C.

    Techniques: Microarray, Immunohistochemical staining, Staining

    Summary of CRABP-II/FABP5 patterns in the cases analyzed and possible predicted outcomes of RA treatment

    Journal: RSC Advances

    Article Title: Differential CRABP-II and FABP5 expression patterns and implications for medulloblastoma retinoic acid sensitivity

    doi: 10.1039/c8ra00744f

    Figure Lengend Snippet: Summary of CRABP-II/FABP5 patterns in the cases analyzed and possible predicted outcomes of RA treatment

    Article Snippet: Rabbit polyclonal antibodies against CRABP-II (ProteinTech 10225-1-AP) or FABP5 (ProteinTech 12348-1-AP), were applied overnight at 4 °C.

    Techniques: